Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00187304

ACTION - Anticoagulation Treatment Influence on Post-operative Patients

Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Abbott Medical Devices · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to compare two different regimens of therapy, AVK and ASA (aspirin), in the early postoperative period after aortic valve replacement with SJM Epic™ or SJM Epic™ Supra Porcine Bioprosthetic Heart Valve by establishing the adverse event free survival rate at 3 month post intervention follow-up of the 2 groups(with special focus on thromboembolic events and bleedings).

Conditions

Interventions

TypeNameDescription
DEVICEAortic valve replacement

Timeline

Start date
2005-09-01
First posted
2005-09-16
Last updated
2019-02-04

Source: ClinicalTrials.gov record NCT00187304. Inclusion in this directory is not an endorsement.

ACTION - Anticoagulation Treatment Influence on Post-operative Patients (NCT00187304) · Clinical Trials Directory